Trialbee, a Swedish patient-recruitment outfit, has added AstraZeneca ($AZN) to its client roster, bringing its direct-to-patient technology to the U.K. drugmaker. Trialbee's platform allows sponsors to tap into online patient groups and scout for potential trial participants, connecting them with motivated patients and potentially bolstering rates of retention and compliance. The deal follows a similar alliance with Novo Nordisk ($NVO). Story